Table 4.

Comparative data for kinase inhibitors in thyroid cancer

CharacteristicsSorafenib30Axitinib29Motesanib28Selumetinib
 Median age, y63 (31–89)59 (26–84)62 (36–81)64 (37–86)
 Male, %50585367
 Prior systemic therapy, %17391723
 Median time from original diagnosis, y4.4 (0.4–21.3)8.6 (0.3–16.9)
 Thyroid cancer subtype, papillary, %605061100
 Thyroid cancer subtype, papillary or follicular, %907596100
Clinical benefit (CR + PR + SD), %76688157
 CR, %0000
 PR, %2330143
 SD, %53386754
 PD, %37828
 PD requirement at study entry, mo12NA6a12
 Median PFS, mo19.718107.5

aStudy required PD using RECIST.

  • Abbreviations: CR, complete response; PR, partial response.